Methods and compositions involving miR-135b for distinguishing pancreatic cancer from benign pancreatic disease

• US 10,655,184 B2
• Filed: 04/19/2017
• Issued: 05/19/2020
• Est. Priority Date: 09/13/2011
• Status: Active Grant

• Current Assignee: Interpace Diagnostics LLC (Interpace Biosciences, Inc.)
• Original Assignee: Interpace Diagnostics LLC (Interpace Biosciences, Inc.)
• Inventors: Adai, Alex, Szafranska-Schwarzbach, Anna, Andruss, Bernard, Hahn, Stephan Albrecht
• Primary Examiner(s): Schnizer, Richard A
• Application Number:
  US15/491,399
• Publication Number:
  US 20180066316A1
• Time in Patent Office: 1,126 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/6844 Nucleic acid amplification reactions
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/178 miRNA, siRNA or ncRNA

Abstract

Provided are methods and compositions for identifying a miRNA profile for a particular condition, such as pancreatic disease, and using the profile in assessing the condition of a patient.

Claims

1. A method of producing amplified, labeled miRNA molecules from a pancreatic sample from a subject, the method comprising:

contacting the pancreatic sample from the subject with primers specific for a group of microRNAs consisting of up to 11 different labeled miRNAs that include at least miR-135b and at least 4 of the following miRNAs;

miR148a, miR-130b, miR-196a, miR-24, miR-375, and miR-96,

wherein miR-217 is not one of the up to 11 different miRNAs; and

reacting the sample with the primers under conditions to amplify the labeled microRNA molecules using polymerase chain reaction to produce the amplified, labeled miRNA molecules.

2. The method of claim 1, wherein the group of microRNAs consists of up to 7 different labeled miRNA molecules.

3. The method of claim 1, wherein the pancreatic sample is a biopsy.

4. The method of claim 3, wherein the biopsy is surgical resection or a fine needle aspirate.

5. The method of claim 1, further comprising obtaining a sample from the subject.

6. The method of claim 1, further comprising labeling the miRNA molecules from a pancreatic sample prior to reacting the sample with the primers.